Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - mitoxantrone (mitozantrone) hydrochloride, quantity: 2.33 mg/ml - injection - excipient ingredients: water for injections; sodium acetate trihydrate; glacial acetic acid; sodium chloride; sodium metabisulfite - mitoxantrone in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. mitoxantrone in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (anll) in adults. this category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - mitoxantrone (mitozantrone) hydrochloride, quantity: 2 mg/ml - injection - excipient ingredients: sodium chloride; water for injections; sodium acetate trihydrate; glacial acetic acid; sodium metabisulfite - mitoxantrone injection, usp is indicated for chemotherapy in patients with: metastatic carcinoma of the breast, relapsed adult leukemia, lymphoma, and hepatoma. in combination with other drug(s), mitoxantrone injection, usp is indicated: in the initial therapy of acute non-lymphocytic leukemia (anll) in adults, including myelogenous, promyelocytic, monocytic and erythroid acute leukemias.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - methotrexate, quantity: 25 mg/ml - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections; sodium chloride; hydrochloric acid - methotrexate injection usp belongs to a group of medicines known as anti-metabolites. it is used in high doses to treat certain types of cancers, including breast cancer, non-hodgkin's lymphoma and leukemia. at lower doses, it may be used to treat psoriasis and severe rheumatoid arthritis.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - cisplatin, quantity: 1 mg/ml - injection - excipient ingredients: water for injections; sodium chloride; sodium hydroxide; mannitol - cisplatin can destroy cells in your body that may cause certain types of cancer (tumour of testis, tumour of ovary, tumour of the bladder, head and neck epithelial tumour, lung cancer and for cervical cancer in combination with radiotherapy).

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - dobutamine hydrochloride, quantity: 14.01 mg/ml (equivalent: dobutamine, qty 12.5 mg/ml) - injection, concentrated - excipient ingredients: sodium metabisulfite; water for injections; hydrochloric acid; sodium hydroxide - dobutamine is indicated for adults who require inotropic support in the treatment of low output cardiac failure associated with organic heart disease, myocardial infarction, open heart surgery, cardiomyophathies, septic shock and cardiogenic shock. dobutamine can increase or maintain cardiac output during positive end expiratory pressure ventilation.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - dacarbazine, quantity: 600 mg - injection, powder for - excipient ingredients: citric acid monohydrate; mannitol; sodium hydroxide - dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. dacarbazine is used as part of combination chemotherapy for the treatment of advanced hodgkin's disease, advanced adult soft tissue sarcomas (except mesothelioma and kaposi sarcoma). dacarbazine has been shown, when used in combination with other cytotoxic agents, to be of use in the treatment of other malignant diseases including carcinoma of the colon, ovary, breast, lung, testicular teratoma, and solid tumours in children.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - bleomycin sulfate, quantity: 15000 iu - injection, powder for - excipient ingredients: - squamous cell carcinoma: skin, larynx and paralarynx, penis, cervix and vulva. lung cancer and cervical carcinoma. lymphomas: hodgkin's lymphoma (no longer treatable by bone marrow depressant agents) and non-hodgkin's lymphoma including reticulum cell sarcoma and lymphosarcoma. testicular carcinoma: embryonal cell carcinoma, choriocarcinoma, and teratocarcimona. pleurodysis and pleural fluid accumulation. renal carcinomas and soft tissue sarcomas.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - bleomycin sulfate, quantity: 15000 iu - injection, powder for - excipient ingredients: - squamous cell carcinoma affecting the mouth, nasopharynx, larynx, paranasal sinuses, oesophagus, external genitalia, cervix or skin. hodgkin's disease and other malignant lymphomas including mycosis fungoides. testicular teratoma. malignant effusions of the serous cavities. metastatic melanoma and the carcinomas of the thyroid, lung and bladder.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - dacarbazine, quantity: 200 mg - injection, powder for - excipient ingredients: citric acid monohydrate; mannitol; sodium hydroxide - dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. dacarbazine is used as part of combination chemotherapy for the treatment of advanced hodgkin's disease, advanced adult soft tissue sarcomas (except mesothelioma and kaposi sarcoma). dacarbazine has been shown, when used in combination with other cytotoxic agents, to be of use in the treatment of other malignant diseases including carcinoma of the colon, ovary, breast, lung, testicular teratoma, and solid tumours in children.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - atracurium besilate, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections; benzenesulfonic acid - atracurium besilate injection is indicated as an adjunct to general anaesthesia during surgery to relax skeletal muscles, and to facilitate endotracheal intubation and mechanical ventilation. it is also indicated to facilitate mechanical ventilation in intensive care unit (icu) patients.